Modulation of sphingosine-1-phosphate receptor ameliorates harmaline-induced essential tremor in rat

Neurosci Lett. 2017 Jul 13:653:376-381. doi: 10.1016/j.neulet.2017.06.015. Epub 2017 Jun 13.

Abstract

Essential tremor (ET) is one of the most common movement disorders with unknown etiology. Despite lack of effective clinical treatments, some potential therapeutic factors and modulation of some neurotransmitters have been utilized to ameliorate motor symptoms in the animal models of tremor. In the current study, male Wistar rats (n=10 in each group) weighing 40-60g were divided into vehicle control groups (saline or DMSO), saline/DMSO+harmaline (30mg/kg, i.p.)+fingolimod (FTY720) (1mg/kg, i.p, 1h before harmaline injection) groups. Open field, rotarod, wire grip and foot print tests were used to evaluate motor function. The results demonstrated that administration of FTY720 can improve harmaline-induced tremor in rats. Moreover, FTY720 ameliorated gait disturbance. The results showed that FTY720 can recover step width, left and right step length; however, FTY720 failed to recover mobility duration. FTY720 also improved falling time and time spent in wire grip and rotarod, respectively. The current study provides the first evidence for the effectiveness of FTY720 on motor function in the harmaline model of ET. Furthermore, neuroprotective effects of FTY720 demonstrated in this study offer sphingosine-1-phosphate receptor (S1PR) modulators as a potential neuroprotective candidate against substance-induced tremor and a possible strategy for the treatment of patients with tremor.

Keywords: Essential tremor; Fingolimod (FTY720); Harmaline; Multiple sclerosis.

MeSH terms

  • Animals
  • Anxiety / chemically induced
  • Anxiety / drug therapy*
  • Behavior, Animal / drug effects*
  • Central Nervous System Stimulants / pharmacology
  • Disease Models, Animal
  • Essential Tremor / chemically induced
  • Essential Tremor / drug therapy*
  • Fingolimod Hydrochloride / administration & dosage
  • Fingolimod Hydrochloride / pharmacology*
  • Gait Disorders, Neurologic / chemically induced
  • Gait Disorders, Neurologic / drug therapy*
  • Harmaline / pharmacology
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / pharmacology*
  • Male
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / pharmacology*
  • Rats
  • Rats, Wistar
  • Receptors, Lysosphingolipid / drug effects*

Substances

  • Central Nervous System Stimulants
  • Immunosuppressive Agents
  • Neuroprotective Agents
  • Receptors, Lysosphingolipid
  • Harmaline
  • Fingolimod Hydrochloride